OIS Presentation

November 11, 2015

ILUVIEN: Revolutionizing DME Treatment

3

The Only DME Treatment of its Kind

Proven to last 36 months (12x

longer than next comparable long-

acting product)

Continuous drug delivery

eliminates the inconsistent

treatment of other more frequently

dosed options

Long term efficacy with a single

injection is patient friendly

Sustained, Multi-Year Approach to

Diabetic Macular Edema

4

Debilitating, Permanent Effects of DME

• Primary cause of vision loss in diabetic

patients

• Leaky blood vessels in the macula cause

the retina to swell

• Causes blurred vision in early stage, over

long term may cause cumulative damage

Photo courtesy of Marinel Casiano CRA and Sanford Chen MD

of Orange County Retina.

5

DME Patients Need More

BCVA 20/20,

15.0%

BCVA 20/40,

31.6%

BCVA 20/60

24.3%

BCVA 20/80

16.4%

BCVA 20/100

12.6%

Source: ASI MR June 2014

~55% of patients

end up 20/60

or worse

Based on Research with MD’s,

BCVA Levels Long Term

(2+ Years) That Their Patients

Achieve

6

Visual Impact

7

ILUVIEN Consistently Delivers

Months

ILU

VIE

N P

atients

With Im

pro

vem

ent in

BC

VA

Fro

m

Base

line

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

0 3 6 9 12 15 18 21 24 27 30 33 36

≥ 1 Letter ≥ 1 Line ≥ 2 Line ≥ 3 Line

Please see ILUVIEN’s Full Prescribing information at www.ILUVIEN.com for important safety information. Data shown from FAME Study.

What are the Doctors and Patients Saying?

9

What are the Doctors and Patients Saying?

Commercial Status

11

ILUVIEN Launch Progress

France

SpainPortugal Italy

Ireland

U.K.

Germany Poland

Belgium

Denmark

Netherlands

Austria

Marketed Approved

CR

United States

CH

12

License Deals

Canada

Australia

Israel

13

Increasing Commercial Sales

Q32013

Q42013

Q12014

Q22014

Q32014

Q42014

Q12015

Q22015

Q32015

$758,000 $935,000

$2,100,000$2,201,000

$2,408,000

$1,741,000

$3,938,000

$5,776,000

$6,910,000

Driving Towards Profitability

14

J Code Available in January

15

Innovation in Ophthalmology

ILUVIEN Geographic Expansion

Patient Friendly

Products

Expanded ILUVIEN Platform

Making a difference in patients lives by

becoming a leading provider in retina care

OIS Presentation

November 11, 2015